| Objective:Gastric cancer is one of the malignant tumors with the highest morbidity and mortality in China,and its sensitivity to traditional treatments such as chemotherapy and radiotherapy is poor,recurrence and metastasis are easy to occur,and the prognosis is poor.Although chemotherapy combined with molecular targeted drug therapy can improve the prognosis of gastric cancer patients to some extent,the curative effect of molecular targeted drug therapy for gastric cancer is limited,and there is still no significant improvement in the treatment of gastric cancer fundamentally.In recent ten years,with the rapid development of medical immunology and molecular biology technology,immunotherapy has gradually become a research hotspot in the field of tumor therapy,and immunotherapy of gastric cancer has attracted great attention.Cancer testes antigen(CTA)is a tumor-specific antigen which is widely studied in the field of immunotherapy at present.CTA is widely expressed in various histological types of malignant tumors and has stronger immunogenicity,that is,it can stimulate patients' humoral and cellular double immune response.So Immunotherapy targeting cancer testis antigen is likely to be a potential therapeutic method for gastric cancer.Researches of immunotherapy targeting CTAs have been carried out in various solid tumors and showed potential effects.It was suggested that patients with gastric cancer may benefit from immunotherapy targeting CTAs.However,there are few data on the expression level and clinical significance in gastric cancer.We explored the expression of NY-ESO-1,MAGE-A1 and KK-LC-1 in gastric cancer,and investigated the clinical significance to find its value in immunotherapy of gastric cancer.Methods:Collected 73 paraffin tissue samples of gastric cancer patients who were diagnosed in Nanjing Gulou hospital from 2015 to 2017,and didn't receive any radiotherapy,chemotherapy or other antitumor treatments before diagnosis.The expression levels of NY-ESO-1,MAGE-A1 and KK-LC-1 protein in tumor tissues were detected by immunohistochemical staining method,and the expression correlations among the three kinds of cancer testis antigen proteins were analyzed.At the same time,the correlation between the expression of these three kinds of cancer testis antigen proteins and clinical pathological features such as sex,age,tumor TNM stage,tumor infiltration depth,lymph node metastasis and intravascular cancer suppository were statistically analyzed.Results:73 gastric cancer patients were randomly selected,among which 55 were male and 18 were female.The median age was 60,ranging from 25 to 78.MAGE-A1,NY-ESO-1 and KK-LC-1 were expressed in 39.73%(29/73),20.55%(15/73)and 9.59%(7/73)of the patients,respectively.NY-ESO-1 expression was significantly correlated with TNM stages(P=<0.001),the positive rate of NY-ESO-1 expression in patients with advanced gastric cancer(stage IV)is significantly higher than that in patients with early stage(stage ?-?).whereas had no significant correlation with age,gender,tumor infiltration depth,lymph node metastasis or intravascular cancer suppository.Meanwhile the expression of MAGE-A1 and KK-LC-1 had no significant correlation with age,gender,tumor TNM stages,tumor infiltration depth,lymph node metastasis or intravascular cancer suppository(P>0.05).NY-ESO-1 expression was positively correlated with both MAGE-A1(P=0.003)and KK-LC-1(P=0.000)levels.However there is no correlation between the expression level of MAGE-A1 and KK-LC-1.Conclusions:MAGE-A1,NY-ESO-1 and KK-LC-1 are expressed in varying degrees in gastric cancer patients.The potential value of these CTA as immunotherapy targets of gastric cancer immunotherapy deserved being further studied. |
PDF Full Text Request